
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen Inc has demonstrated a positive growth trajectory with a 13.6% compound annual growth rate (CAGR) in revenue since 2020, highlighting the company's consistent performance in the peripheral nerve regeneration market. The increasing reimbursement rates for allograft procedures, including a 138% rise for ambulatory surgery centers since 2019, indicate a strengthening market environment that could enhance the company's profitability. Furthermore, the potential for sustainable profitability by 2026, driven by expanding market penetration in various surgical applications, further supports a favorable outlook for the company's stock.
Bears say
Axogen Inc. faces numerous risks that contribute to a negative outlook on its stock, including potential lower-than-expected sales growth stemming from competition, regulatory hurdles, and technological advancements that could render its products obsolete. The company has a history of net losses and is highly dependent on key management and market acceptance, while increased competition from alternative nerve repair products poses a threat to its revenue and market share. Additionally, uncertainties surrounding the regulatory approval process for its flagship product, Avance, along with challenges related to scaling operations and managing supply chain issues, further undermine Axogen's growth prospects and sustainable profitability.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares